论文部分内容阅读
伴有冠心病的高血压惠者,不论选用β-受体阻滞剂还是钙拮抗剂作为控制血压的一线药物,最后结果是一样的。 Gainesville市佛罗里达大学医学院的Carl Pepine博士及其同事随机入选了22 576例高血压伴有冠心病的患者,入选患者年龄均在50岁以上,随机接受缓释的维拉帕米或阿替洛尔作为降压治疗的一线药物,该项研究入选患者来源于14个国家的862个医疗中心,在1997～2003年完成(JAMA 2003;290:2805-16)。
High blood pressure associated with coronary heart disease beneficiaries, regardless of the choice of β-blockers or calcium antagonists as first-line drugs to control blood pressure, the final result is the same. Dr. Carl Pepine and colleagues at the University of Florida Medical School in Gainesville enrolled a total of 22 576 patients with hypertension and coronary heart disease. All patients were over 50 years of age and were randomized to receive sustained-release verapamil or atebolol As the first-line drug for antihypertensive treatment, the study population was enrolled in 862 medical centers in 14 countries and was completed between 1997 and 2003 (JAMA 2003; 290: 2805-16).